Pharmaceuticals News and Research

RSS

IMAI formally offered to purchase equity position in pharmaceutical operation

International Merchant Advisors, Inc. announced today that the company has formally offered to purchase an equity position in a pharmaceutical operation that is focused on selling in the chronic pain management medical sector.

15 Feb 2010

Symposium exploring future of cancer research to be hosted at GUMC

The Georgetown Lombardi Comprehensive Cancer Center hosts a symposium exploring the future of cancer research on Feb. 17th at Georgetown University Medical Center. Sponsored by the Ruesch Center for the Cure of Gastrointestinal Cancers, the two-part symposium, "Fighting a Smarter War Against Cancer: Personalized Medicine & the Cure for Cancer," will offer a focus on personalized medicine by bringing together experts in academia, industry and advocacy.

15 Feb 2010

Wyoming lawkmaker pushes for reform, Mississippi Governor bans certain over-the-counter drugs

Associated Press/CNBC: "A veteran Wyoming state senator for the third time is pushing a bill he says would offer health insurance to people who couldn't afford it on the open market and also serve as an example to the rest of the nation of how to tackle rising health care costs. Sen. Charles Scott, R-Casper, has proposed a pilot program that calls for allowing 500 participants to enroll in Medicaid beginning in July. It would be limited to people whose family income is below 250 percent of the federal poverty level — $55,125 for a family of four.

15 Feb 2010

Idera Pharmaceuticals presents TLR antagonist preclinical hyperlipidemia data at Keystone Symposia conference

Idera Pharmaceuticals, Inc. presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference “Advances in Molecular Mechanisms of Atherosclerosis” being held in Banff, Alberta, Canada. Idera’s proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and present a potentially innovative approach for the treatment of certain autoimmune diseases.

15 Feb 2010

Euthymics Bioscience signs LOI to acquire DOV Pharmaceutical

Euthymics Bioscience, Inc., a privately held Delaware corporation, today announced that it has signed a non-binding Letter of Intent (LOI) to merge into and acquire DOV Pharmaceutical, Inc. (DOV), a Delaware corporation currently traded on the Pink Sheets, for $2.0 million in cash plus payment of certain of DOV's expenses. DOV believes that the contemplated $2.0 million cash payment to shareholders represents approximately $0.015 per share of DOV common stock. If the transaction is consummated, it is anticipated that DOV will be renamed Euthymics Bioscience, Inc.

12 Feb 2010

Merck returns worldwide development and commercialization rights for AN2690 to Anacor Pharmaceuticals

Anacor Pharmaceuticals announced today that Merck has returned full worldwide development and commercialization rights for AN2690 to Anacor. AN2690 is a topical anti-fungal therapy being developed for onychomycosis, a fungal infection of the nail and nail bed. It is estimated that onychomycosis affects approximately 35 million people in the United States.

12 Feb 2010

EMBL-EBI hosts ChEMBLdb online database

ChEMBLdb, an online database of information on the properties of more than half a million drug and drug-like small molecules and their targets, has been launched.

12 Feb 2010

Viral Genetics: Company update

Our mission is to bring new drug compounds to the marketplace. And we've never been in a stronger position to deliver on that promise. We've built the solid foundation needed to take drug therapies from the laboratory to the marketplace. After years in development, we believe several of our most promising compounds are moving closer to clinical trials.

12 Feb 2010

First Edition: February 12, 2010

Today's headlines highlight the continuing flap over Anthem Blue Cross' planned rate hike as well as GOP and Democratic responses to President Obama's proposed health summit.

12 Feb 2010

ISMPP announces opening of registration for 6th annual meeting on medical publications

The International Society for Medical Publication Professionals (ISMPP) is pleased to announce the opening of registration for its 6th annual meeting, "Delivering Value and Driving Advocacy in Medical Publications." The meeting will run from April 19 to 21, 2010, in Arlington, VA, at the Crystal Gateway Marriott.

12 Feb 2010

Smart Holograms launches new Verif-EYE bio-optical, interactive visual sensor

Today, Smart Holograms, a UK-Based Technology Company, announced the commercial availability of its new Verif-EYE™ bio-optical, interactive visual sensor that allows consumers to ‘self validate’ their purchases prior to consumption or use to ensure the product is genuine and tamper-free.

12 Feb 2010

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ToleroMune(R) ragweed allergy T-cell vaccine achieved positive results in a recently completed phase II clinical trial. Ragweed allergy is particularly common in America, where it affects approximately 25% of the population. Circassia's latest clinical results follow two earlier successful phase II studies with the company's T-cell vaccine against cat allergy.

12 Feb 2010

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. Cotara is currently being tested in a Phase II clinical trial in recurrent GBM patients.

12 Feb 2010

Formatech issued patent covering novel formulation methods to enhance solubility of certain hydrophobic compounds

Today, Formatech, Inc. announced the issuance of U.S. patent 7,659,310, entitled “Methods of Enhancing Solubility of Agents” which covers novel formulation methods to enhance the solubility of certain hydrophobic compounds.

12 Feb 2010

Sun Knowledge to attend Annual Drug Benefit Conference in Phoenix

Sun Knowledge, Ltd., a leading Healthcare Insurance provider of Knowledge Process Outsourcing (KPO) services, will attend the Pharmacy Benefit Management Institute’s Annual Drug Benefit Conference in Phoenix, Az., from February 17-19.

12 Feb 2010

Third party reexamination of Phase III study of Ereska meets primary endpoint

Javelin Pharmaceuticals, Inc. today announced that a reexamination conducted by a third party of pain score measurements from its Phase III study of Ereska™ (intranasal ketamine) showed that top line results for its primary endpoint were statistically significant. Previously, Javelin had reported that the top line results for its primary endpoint were not statistically significant.

12 Feb 2010

NeoStem prices public offering of 5M common stock shares at $1.35 per share

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it priced a public offering of 5,000,000 shares of its common stock at $1.35 per share. Net proceeds from the offering, after underwriting discounts and commissions and expenses, will be approximately $5,697,500. NeoStem has granted the underwriters an option to purchase up to an additional 750,000 shares to cover over-allotments, if any.

12 Feb 2010

Low doses of antibiotics may serve as active mutagens and lead to multidrug resistance

Multidrug resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA) pose a major problem for patients, doctors, and the pharmaceutical industry. To combat such bacteria, it is critical to understand how resistance is developed in the first place. It is commonly thought that an incomplete course of antibiotics would lead to resistance to that particular antibiotic by allowing the bacteria to make adaptive changes under less stringent conditions.

12 Feb 2010

IBM, VLSCI scientists to use Blue Gene supercomputer to study human disease

IBM today announced a Research collaboratory in Melbourne, Australia, where scientists from the Victorian Life Sciences Computational Initiative at the University of Melbourne and the IBM Research Computational Biology Center will use high performance computing – including IBM's Blue Gene supercomputer – to study human disease.

12 Feb 2010

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, today presented positive results from its first Phase III study (TKT 032) evaluating safety and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease. The data were presented in an oral presentation at the Lysosomal Disease Network (LDN) World Symposium in Miami, Florida.

12 Feb 2010

Pharmaceuticals News and Research

IMAI formally offered to purchase equity position in pharmaceutical operation

Symposium exploring future of cancer research to be hosted at GUMC

Wyoming lawkmaker pushes for reform, Mississippi Governor bans certain over-the-counter drugs

Idera Pharmaceuticals presents TLR antagonist preclinical hyperlipidemia data at Keystone Symposia conference

Euthymics Bioscience signs LOI to acquire DOV Pharmaceutical

Merck returns worldwide development and commercialization rights for AN2690 to Anacor Pharmaceuticals

EMBL-EBI hosts ChEMBLdb online database

Viral Genetics: Company update

First Edition: February 12, 2010

ISMPP announces opening of registration for 6th annual meeting on medical publications

Smart Holograms launches new Verif-EYE bio-optical, interactive visual sensor

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

Formatech issued patent covering novel formulation methods to enhance solubility of certain hydrophobic compounds

Sun Knowledge to attend Annual Drug Benefit Conference in Phoenix

Third party reexamination of Phase III study of Ereska meets primary endpoint

NeoStem prices public offering of 5M common stock shares at $1.35 per share

Low doses of antibiotics may serve as active mutagens and lead to multidrug resistance

IBM, VLSCI scientists to use Blue Gene supercomputer to study human disease

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence